The Column Group
The Column Group is a leading venture capital firm dedicated to creating the next generation of biotechnology companies. We will deploy our first fund of approximately $260M to build 8-10 disease-focused drug discovery companies, each with the potential to become a leader in their respective field(s). These companies will be strongly supported by the unique and complementary skill-sets of our team, which includes prominent authorities in the scientific, operational and financial arenas. Typically, we will commit $20M to $30M per company, fostering their growth from seed and early stage to later stages of development. The Column Group seeks to partner with exceptional scientific founders, entrepreneurs, executives and investment organizations that share our vision for building the next generation of drug discovery and development companies.

Prospect Venture Partners
Prospect Venture Partners is a Palo Alto, California based venture capital firm with over $1B of capital under management. The firm is dedicated to investing in outstanding biopharmaceutical and medical device companies. Prospect targets commercially attractive biomedical enterprises with outstanding entrepreneurial management teams, proprietary products, and innovative technologies with the potential for significant investment returns. The firm invests in companies with a wide variety of development and financing requirements including new company incubations, first and second venture financing rounds, and later stage private and public companies with proven business models requiring expansion capital.

Rho Ventures
Rho is a diversified private equity firm dedicated to providing exceptional results for its investors.

Since 1981 Rho Ventures has been investing in leading edge, high growth companies that redefine the status quo. The firm has a deep history of supporting companies at multiple stages of growth spanning early stage investments to later stage expansion and growth equity transactions. Rho Ventures has financed approximately 200 companies and has invested in market leaders across many high growth sectors including information technology, communications, new media, healthcare and energy technology.